{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05483075",
            "orgStudyIdInfo": {
                "id": "22-00289"
            },
            "organization": {
                "fullName": "NYU Langone Health",
                "class": "OTHER"
            },
            "briefTitle": "Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer",
            "officialTitle": "An Exploratory Study Evaluating the Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer With Biological Correlative Studies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "feasibility-of-a-health-care-provider-guided-exercise-intervention-prior-to-surgical-resection-of-pancreatic-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-29",
            "studyFirstSubmitQcDate": "2022-07-29",
            "studyFirstPostDateStruct": {
                "date": "2022-08-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NYU Langone Health",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Pilot study evaluating the feasibility of a 2-4 week health care provider guided exercise intervention prior to surgery for pancreatic cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Cancer"
            ],
            "keywords": [
                "HCP-Guided Exercise"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HCP-Guided Exercise",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will schedule twice-weekly in-person visits to conduct health care provider (HCP)-supervised exercise activity for a minimum of 30 minutes. At least 3 additional times per week, participants will conduct self-directed exercise at home. Activity and other outcomes will be monitored with an Actigraph Centrepoint Insight Watch.\n\nThe HCP guided therapy will continue on a weekly basis for at least 2 weeks and up to a maximum of 4 weeks.",
                    "interventionNames": [
                        "Behavioral: HCP-Guided Exercise Training Program"
                    ]
                },
                {
                    "label": "Control",
                    "type": "NO_INTERVENTION",
                    "description": "Participants will not participate in the HCP-guided exercise intervention but will wear the Actigraph Centrepoint Insight Watch."
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "HCP-Guided Exercise Training Program",
                    "description": "Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).\n\nTwo days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.\n\nThe remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR).",
                    "armGroupLabels": [
                        "HCP-Guided Exercise"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention",
                    "description": "Compliance with HCP exercise intervention is defined as successful completion of at least 150 minutes of weekly moderate-to-intense physical activity over a minimum of 2 weeks for every week of the prescribed intervention (2, 3 or 4 weeks).",
                    "timeFrame": "Up to Week 4"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of Participants who Experience Adverse Events (AEs)",
                    "description": "AEs defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study.",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Number of Participants who Experience an Event that Leads to Delay in Surgical Resection",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Change in Number of Tumor-Infiltrating CD8-Positive T Cells",
                    "description": "Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of cluster designation 8 (CD8)-positive T cells.",
                    "timeFrame": "Baseline, Final Study Visit (Between Weeks 2-4)"
                },
                {
                    "measure": "Change in Number of Tumor-Infiltrating CD8-Positive T Cells Expressing IL-15Ra",
                    "description": "Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of CD8-positive T cells expressing Interleukin 15 Receptor Alpha Subunit (IL-15Ra).",
                    "timeFrame": "Baseline, Final Study Visit (Between Weeks 2-4)"
                },
                {
                    "measure": "Change in Number of Tumor-Infiltrating CD8-Positive T Cells Expressing GZMB",
                    "description": "Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of CD8-positive T cells expressing Granzyme B (GZMB).",
                    "timeFrame": "Baseline, Final Study Visit (Between Weeks 2-4)"
                },
                {
                    "measure": "Change in Number of Tumor-Infiltrating CD8-Positive T Cells Expressing CD3",
                    "description": "Multiplex immune-fluorescence staining conducted on tumor tissue samples to assess number of CD8-positive T cells expressing cluster designation 3 (CD3).",
                    "timeFrame": "Baseline, Final Study Visit (Between Weeks 2-4)"
                },
                {
                    "measure": "Change in Number of Circulating CD8-Positive T Cells Expressing IL-15Ra as Assessed by Flow Cytometry",
                    "description": "Flow cytometry conducted on patient blood samples to assess number of circulating CD8-positive T cells expressing Interleukin 15 Receptor Alpha Subunit (IL-15Ra).",
                    "timeFrame": "Baseline, Final Study Visit (Between Weeks 2-4)"
                },
                {
                    "measure": "Time Spent in Moderate-to-Vigorous Physical Activity (MVPA)",
                    "description": "Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms.\n\nModerate Activity is defined as between 3.00 and 5.99 metabolic equivalents (METs). Vigorous Activity is defined as at least 6.00 METs. MET is defined as the ratio of the work metabolic rate to the resting metabolic rate.",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Time Spent in Sedentary Behavior",
                    "description": "Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms.\n\nSedentary Behavior is defined as less than 0.11 metabolic equivalents (METs). MET is defined as the ratio of the work metabolic rate to the resting metabolic rate.",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Average Daily MET Rates",
                    "description": "Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms.\n\nMET is defined as the ratio of the work metabolic rate to the resting metabolic rate. Light intensity activities are defined as less than 3 METs, moderate intensity activities are defined as between 3 and 5.99 METs, and vigorous intensity activities are defined as 6 METs or greater.",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Total Physical Activity Energy Expenditure",
                    "description": "Monitored using the ActiGraph Centrepoint Insight Watch in conjunction with ActiLife software and validated algorithms. Expressed in kcal/day.",
                    "timeFrame": "Up to Week 4"
                },
                {
                    "measure": "Minutes Spent in Rapid Eye Movement (REM) Sleep",
                    "description": "Monitored using ActiGraph Centrepoint Insight Watch.",
                    "timeFrame": "Up to Week 4"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Willingness and ability to participate in the study procedures\n2. Pathologically confirmed pancreatic cancer\n3. Candidate for neoadjuvant therapy followed by surgical resection with potentially curative intent. Note: There is no limitation on duration of neoadjuvant therapy.\n4. Planned to have at least 2 weeks after completing the last neoadjuvant therapy and surgery\n5. Over the age of 18\n6. Ability to engage in physical activity as determined by physiatrist review after completion of the Physical Activity Readiness questionnaire (PAR-Q) exercise survey and chart review\n7. Agree to study blood draws and tissue collection\n\nExclusion Criteria:\n\n1. Evidence of metastatic disease\n2. Inability to complete physical activity due to recent injury or surgery\n3. Uncontrolled heart disease limiting physical activity\n4. Participation in another interventional trial that excludes participation in this protocol\n5. Subjects who anticipate undergoing a procedure during the course of the trial that will render them unable to engage in physical activity for more than 48 hours\n6. Pregnant subjects\n7. Individuals who lack the capacity to consent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "90 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Paul Oberstein, MD",
                    "role": "CONTACT",
                    "phone": "212-731-6120",
                    "email": "paul.oberstein@nyulangone.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Paul Oberstein, MD",
                    "affiliation": "NYU Langone Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "NYU Langone Health Ambulatory Care Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Paul Oberstein, MD",
                            "role": "CONTACT",
                            "phone": "212-731-6120",
                            "email": "paul.oberstein@nyulangone.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to:\n\nPaul Oberstein 212-731-6120 paul.oberstein@nyulangone.org\n\nThe protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.",
            "accessCriteria": "The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to paul.oberstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}